November 17, 2026 FDA approves giredestrant for breast cancer Median progression-free survival was 10 vs 5.5 months with giredestrant vs comparator therapy. MDSpire News
November 17, 2026 FDA approves new pertuzumab biosimilar Approved for metastatic and early-stage breast cancer, the biosimilar cannot launch in the US before Q3 2028. MDSpire News
November 17, 2026 Can PET help spare chemo in HER2-positive breast cancer? Five-year findings show favorable disease control among selected patients, while ctDNA may offer additional insight into recurrence risk. MDSpire News
November 16, 2026 FDA rejects ivonescimab for lung cancer Longer disease control without a statistically significant survival benefit did not support approval. MDSpire News
November 13, 2026 FDA approves durvalumab for bladder cancer The agency granted priority review and approved the bladder cancer regimen 6 weeks ahead of schedule. MDSpire News
November 10, 2026 New oral option for TGCT when surgery poses risks The FDA approved a once-daily oral treatment for adults with symptomatic tenosynovial giant cell tumor. MDSpire News
November 06, 2026 FDA approves amivantamab for head and neck cancer Accelerated approval follows a 42% response rate in 102 patients previously treated with chemotherapy and immunotherapy. MDSpire News
November 06, 2026 Can red tattoos harbor keratoacanthoma? A rapidly growing forearm nodule developed within weeks of tattoo placement, adding to previous reports of tumors arising in red pigment. MDSpire News
November 04, 2026 Low PET uptake may mask aortic sarcoma Recurrent arterial embolization prompted surgery after imaging suggested thrombus, but definitive pathology revealed malignancy. MDSpire News
November 03, 2026 AI may cut breast biopsy review time by 44% A paired-reader study found that pathologists maintained high diagnostic agreement while reviewing breast biopsy slides faster with AI assistance. MDSpire News